LataMed AI Corp. Reports Going Concern Doubt, Material Control Weakness, and New Super-Voting Preferred Stock
LMED has more than doubled off its 52-week low of $0.265.
Summary
LataMed AI Corp. reported a going concern warning, material weakness in internal controls, zero revenue, and a new Series C super-voting preferred stock, highlighting severe financial distress and governance changes.
Key Events · Corporate Governance and Compliance · LMED
-
Going Concern Warning Issued
The company reported net losses of $52,813 for the quarter and accumulated deficits of $29,653,599, raising substantial doubt about its ability to continue as a going concern. The company has no cash and a working capital deficit of $683,673.
-
Material Weakness in Internal Controls
Management concluded that financial disclosure controls and procedures were not effective due to limited internal resources and lack of multiple levels of transaction review.
-
New Series C Voting Preferred Stock Authorized
Subsequent to the quarter, the Board approved a new Series C Voting Preferred Stock with 5,000,000 authorized shares, granting 20 votes per share, which is non-convertible and has a liquidation preference senior to common stock.
-
Zero Revenue and Increased Net Loss
The company reported no revenue for the quarter ended March 31, 2026, and its net loss increased to $52,813 from $24,455 in the prior year period.
Analysis · LMED · Technology
LataMed AI Corp. faces substantial doubt about its ability to continue as a going concern, reporting zero cash, increasing net losses, and a worsening working capital deficit. The company is entirely dependent on external funding. Compounding these financial challenges, management identified a material weakness in internal controls over financial reporting. Furthermore, the Board authorized a new Series C Voting Preferred Stock with 20 votes per share, which could significantly concentrate voting power and impact corporate governance.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LMED was trading at $2.73 on OTC in the Technology sector, with a market capitalization of approximately $153.2M. The 52-week trading range was $0.27 to $2,025.02. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.